Several successive generations of TKIs have been approved in an effort to address the BCR::ABL1 point mutation resistance vulnerabilities of CML patients, however, predicting BP progression and effectively treating BP patients with resistance remains an area of clinical challenge. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.